CSIMarket Company Name, Ticker, Industry, else..
 
Skye Bioscience Inc   (SKYE)
Other Ticker:  
 
 
Price: $5.2800 $-0.52 -8.966%
Day's High: $6.01 Week Perf: -16.85 %
Day's Low: $ 5.15 30 Day Perf: 13.3 %
Volume (M): 125 52 Wk High: $ 19.41
Volume (M$): $ 659 52 Wk Avg: $7.27
Open: $5.96 52 Wk Low: $1.44



 Market Capitalization (Millions $) 204
 Shares Outstanding (Millions) 39
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -41
 Cash Flow (TTM) (Millions $) 84
 Capital Exp. (TTM) (Millions $) 0

Skye Bioscience Inc
Skye Bioscience Inc is a biotechnology company focused on developing and commercializing novel therapeutics for various medical conditions. The company's primary area of research is the endocannabinoid system, which plays a crucial role in regulating various physiological processes. Skye Bioscience aims to leverage its expertise in this area to develop innovative drugs that target specific components of the endocannabinoid system to address unmet medical needs. The company's pipeline includes potential treatments for glaucoma, ocular inflammation, and neuroinflammatory conditions. Skye Bioscience is committed to advancing its drug candidates through rigorous clinical development and regulatory approval processes to bring transformative therapies to patients.


   Company Address: 11250 El Camino Real, San Diego 92130 CA
   Company Phone Number: 410-0266   Stock Exchange / Ticker: NASDAQ SKYE


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Management Changes

Skye Bioscience Appoints Dr. Puneet S. Arora as CMO to Navigate Financial Turbulence and Pave the Way for Metabolic Health Breakthroughs,

Published Tue, Sep 3 2024 11:01 AM UTC


By
City, - Skye Bioscience, a clinical-stage biopharmaceutical company dedicated to uncovering innovative therapeutic avenues for metabolic health, has recently announced the appointment of Dr. Puneet S. Arora as its new Chief Medical Officer (CMO). This strategic move comes at a crucial time for Skye Bioscience, which has been grappling with significant financial...
Shares

Skye Bioscience Grants Non-Qualified Stock Options to New Employee, Demonstrating Commitment to Unlocking Therapeutic Pathways for Metabolic Health

Published Fri, Aug 23 2024 10:45 PM UTC



SAN DIEGO, Aug. 23, 2024 - Skye Bioscience, a clinical-stage biopharmaceutical company specializing in discovering innovative therapeutic pathways for metabolic health, has announced the granting of a non-qualified stock option award to a new non-executive employee under the 2024 Inducement Equity Incentive Plan (the 2024 Inducement Plan). This strategic move by Sk...
Clinical Study

Skye Bioscience Embarks on Groundbreaking Phase 2 Trial to Tackle Obesity with Nimacimab

Published Thu, Aug 22 2024 11:00 AM UTC

In an exciting development in the field of obesity treatment, Skye Bioscience has announced the launch of its Phase 2 clinical trial, known as the CBeyond trial, to evaluate the efficacy and safety of its innovative CB1 inhibitor, nimacimab. This clinical trial aims to address one of the most pressing health concerns globally: obesity, which affects millions of individuals a...
Partnership

Skye Bioscience Reveals Phase 2 Nimacimab Trial with Focus on Metabolic Rewiring and Sleep Apnea in Collabo...

Published Wed, Jul 24 2024 10:00 AM UTC

In a compelling virtual Key Opinion Leader (KOL) event, Skye Bioscience recently unveiled comprehensive insights into their innovative work on metabolic rewiring via CB1 inhibition. Central to the event was the detailed discussion on the upcoming Phase 2 clinical trial for Nimacimab, alongside their new collaboration with Beacon Biosignals aimed at evaluating the potential i...
Stocks on the Move

Skye Bioscience Inc Analyzing the Under-Performance and Future Prospects

Published Fri, Jul 12 2024 5:17 PM UTC

In recent weeks, Skye Bioscience Inc's shares have shown a significant under-performance compared to the overall market. This article aims to examine the key events and factors that may have contributed to this decline. Furthermore, it will delve into the company's financial performance and market capitalization to provide a comprehensive analysis of Skye Bioscience Inc's cu...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com